Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13165825 | 0.82 | RORC (0.33) | — | |
| SCHEMBL21400958 | 0.80 | USP2 (0.41) | CA12CA7CA14KDM4EHSD17B10 | |
| SCHEMBL4974769 | 0.77 | MEN1 (0.51) | CA12CA7CA14KDM4EHSD17B10 | |
| SCHEMBL778651 | 0.77 | CHRM2 (0.41) | ALOX15 | |
| SCHEMBL15464645 | 0.77 | — | — | |
| SCHEMBL4021995 | 0.76 | KDM4E (0.45) | CA12CA7CA14KDM4EHSD17B10 | |
| SCHEMBL5516652 | 0.76 | KDM4E (0.45) | CA12CA7CA14KDM4EHSD17B10 | |
| SCHEMBL2377137 | 0.76 | CA12 (0.42) | CA12CA7CA14KDM4EHSD17B10 | |
| SCHEMBL14997963 | 0.76 | ALDH1A1 (0.43) | CA12CA7CA14KDM4EHSD17B10 | |
| SCHEMBL27601991 | 0.76 | HSD17B10 (0.41) | CA12CA7CA14KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140206865-A1 | Human Adam-10 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20130144056-A1 | Human Adam-10 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-8450373-B2 | Alpha ketoamide compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120270884-A1 | Methods of Treating Aneurysmal Dilatation, Blood Vessel Wall Weakness and Specifically Abdominal Aortic and Thoracic Aneurysm Using Matrix Metalloprotease-2 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| EP-2511257-A2 | Alpha ketoamide compounds as cysteine protease inhibitors | ViroBay, Inc. (US) | 2012-10-17 | — | — | EP | disclosed |
| US-8247451-B2 | ADAM10 and its uses related to infection | VANDERBILT UNIVERSITY (US) | 2012-08-21 | — | — | US | disclosed |
| US-20120190714-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | APPLERA CORPORATION (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120071653-A1 | Human Adam-10 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-8013183-B2 | Alpha ketoamide compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-7989661-B2 | Human ADAM-10 inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110082114-A1 | Methods of Treating Aneurysmal Dilatation, Blood Vessel Wall Weakness and Specifically Abdominal Aortic and Thoracic Aneurysm Using Matrix Metalloprotease-2 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20100305331-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | VIROBAY, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100105953-A1 | Human Adam-10 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-7696250-B2 | Alpha ketoamide compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7629341-B2 | e.g. N1-hydroxy-N2-[(4-phenoxyphenyl)sulfonyl]-D-argininamide; metallopeptidase inhibitor; antiinflammation, anticarcinogenic, antidiabetic agent; angiogenesis inhibitor; atherosclerosis, stroke, ulcer, infertility, scleroderma, endometriosis, mesothelioma | SYMPHONY EVOLUTION, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20090220514-A1 | ADAM10 and its Uses Related to Infection | VANDERBILT UNIVERSITY | 2009-09-03 | — | — | US | disclosed |
| US-20090170909-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | VIROBAY, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-7488848-B2 | Alpha ketoamide compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2009-02-10 | — | — | US | disclosed |
| US-20070021353-A1 | Alpha ketoamide compounds as cysteine protease inhibitors | APPLERA CORPORATION (US) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190714-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CTSS, CTSF, CTSB | CA12 821/4885CA7 540/4885CA14 933/4885 |
| US-20120270884-A1 | Methods of Treating Aneurysmal Dilatation, Blood Vessel Wall Weakness and Specifically Abdominal Aortic and Thoracic Aneurysm Using Matrix Metalloprotease-2 Inhibitors | ADAM10, ADAM17, ADAM12 | CA12 645/4885CA7 612/4885CA14 1482/4885 |
| US-20090170909-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CTSS, CTSF, CTSB | CA12 821/4885CA7 540/4885CA14 933/4885 |
| US-20070021353-A1 | Alpha ketoamide compounds as cysteine protease inhibitors | CTSS, CTSF, CTSB | CA12 821/4885CA7 540/4885CA14 933/4885 |
| US-20120071653-A1 | Human Adam-10 Inhibitors | ADAM10, MMP20, ADAM9 | CA12 625/4885CA7 604/4885CA14 588/4885 |
| US-20100105953-A1 | Human Adam-10 Inhibitors | ADAM10, MMP20, ADAM9 | CA12 625/4885CA7 604/4885CA14 588/4885 |
| US-20110082114-A1 | Methods of Treating Aneurysmal Dilatation, Blood Vessel Wall Weakness and Specifically Abdominal Aortic and Thoracic Aneurysm Using Matrix Metalloprotease-2 Inhibitors | ADAM10, ADAM17, ADAM12 | CA12 945/4885CA7 896/4885CA14 1970/4885 |
| US-20090220514-A1 | ADAM10 and its Uses Related to Infection | ADAM10, ADAM12, ADAM17 | CA12 498/4885CA7 1515/4885CA14 521/4885 |
| US-20100305331-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CTSS, CTSF, CTSB | CA12 821/4885CA7 540/4885CA14 933/4885 |
| US-20140206865-A1 | Human Adam-10 Inhibitors | ADAM10, MMP20, ADAM9 | CA12 625/4885CA7 604/4885CA14 588/4885 |
| US-20130144056-A1 | Human Adam-10 Inhibitors | ADAM10, MMP20, ADAM9 | CA12 625/4885CA7 604/4885CA14 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.